Navigation Links
VAP(R) Cholesterol Test Helps Researchers Identify Treatment Effects of Combination Therapy
Date:11/10/2008

s with mixed hyperlipidemia were randomized to one of four treatment groups: placebo; ezetimibe/simvastatin (10/20 mg/d); fenofibrate (160 mg/d); or ezetimibe/simvastatin (10/20 mg/d) + fenofibrate (160 mg/d) for 12 weeks. The primary efficacy endpoint of the trial was percent change in LDL-C from baseline to study endpoint after treatment with ezetimibe/simvastatin + fenofibrate versus fenofibrate alone.

Detailed evaluation of the effects of ezetimibe/simvastatin and fenofibrate both as monotherapy and in coadministration was achieved by examining their effects on individual lipoprotein subclasses. Cholesterol associated with very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), LDL and HDL subfractions was quantified using the Vertical Auto Profile method. LDL particle size was determined using segmented gradient gel electrophoresis (S3GGE(TM) Berkeley Heart Lab).

A key feature of the comprehensive VAP Test is the identification of the major lipid components of residual risk leading to proper individualized therapy. The VAP Test provides researchers and medical professionals with direct measurement of LDL, HDL and all relevant subclasses, and includes non-HDL, a highly accurate determination of apoB, and emerging risk factors such as Lp(a), remnants and small dense LDL.

"We're pleased that the VAP Test was essential in helping investigators identify an optimal combination of therapies for the treatment of mixed hyperlipidemia," said James Ehrlich, M.D., Atherotech's chief medical officer. "Examining in detail the effect of these therapies on lipoprotein subclasses should lead to improved treatment of at-risk individuals exhibiting elevated LDL, triglycerides and non-high density lipoprotein (HDL) cholesterol plus low HDL."

Researchers reported that ezetimibe/simvastatin and fenofibrate, both as separate therapy and in coadministration, produced beneficial changes in the distribution of lipoprotein subclasses withi
'/>"/>

SOURCE Atherotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VAP(R) Cholesterol Test Bolsters Biophysical(R) Health Assessment
2. VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured
3. Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008
4. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
5. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
6. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
7. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
8. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
9. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
10. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
11. New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, ... Strategy. In this role, Michelle will work with current and ... the development of iLab products. Her main goal will be ... the scientific community by offering the most advanced, user-friendly, and ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), ... commercializing innovative therapies addressing major unmet medical needs ... the Notice of Allowance from the United States ... RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. ...
(Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Globally, approximately 418 million,people are currently infected with ... hepatitis in the 21st century cannot be,understated or ... by Kalorama Information. Paradoxically, despite the obvious ... to contain hepatitis. Yet the incidence and,prevalence of ...
... Tuesday, September 11, 2007 - 11:00 a.m. ET; 8:00 ... 6 /PRNewswire-FirstCall/ - MIGENIX,Inc. (TSX: MGI; OTC: MGIFF), a ... conference call and webcast on Tuesday,September 11, 2007 at ... for the first fiscal quarter ended July 31, 2007. ...
... Inc.,(Nasdaq: VRUS ) and Roche (OTC: RHHBY) ... for the treatment of chronic hepatitis C,virus (HCV) ... on Hepatitis C,Virus and Related Viruses being held ... prodrug of PSI-6130, is an oral cytidine nucleoside,analog ...
Cached Biology Technology:Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health 2MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 3Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 4Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 5
(Date:4/17/2014)... Our eyes not ... with a continuous stream of information about our own movements. ... a car the world glides by us and leaves ... our brain calculates self-motion from this "optic flow". This way, ... during our own movements. Together with biologists from the University ...
(Date:4/17/2014)... Rajendra Singh Thursday as a "Champion of Change" ... deployment in the residential, commercial and industrial sectors. ... Electrical and Computer Engineering and director of Clemson,s ... hero leading the charge across the country to ... and driving policy changes at the local level ...
(Date:4/17/2014)... a novel method to help kidney stone sufferers ... treatment possible., Kidney stones represent a major medical ... left untreated, apart from being particularly painful, they ... In many patients treated successfully, stone recurrence is ... approach to diagnosis and treatment needs to be ...
Breaking Biology News(10 mins):How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... shedding light on possible causes of infertility and autoimmune ... and florescent genes to illuminate cells that produce a ... lupus. The technique will help scientists track the ... ensuring supplies of breast milk in nursing mothers but ...
... Belfast academic has shown that crabs not only suffer pain ... study, which looked at the reactions of hermit crabs to ... and Mirjam Appel from the School of Biological Sciences at ... Behaviour . Professor Elwood, who previously carried out a ...
... fish stocking has on aquatic insects in mountain lakes ... to a study completed by U.S. Forest Service and ... a current online issue of the journal Freshwater Biology ... fisheries management practices now in use in California mountain ...
Cached Biology News:Crabs' memory of pain confirmed by Queen's academic 2Study assesses impact of fish stocking on aquatic insects 2
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
Mouse monoclonal antibody raised against a partial recombinant MYO7A. NCBI Entrez Gene ID = MYO7A...
... PrecisION Ion Channel Cell Lines ,High ... ,Ion channels are well known for having ... function and consequently have a key function ... that modulate ion channels have been investigated ...
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Biology Products: